Does OCRELIZUMAB Cause Mobility decreased? 539 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 539 reports of Mobility decreased have been filed in association with OCRELIZUMAB (OCREVUS). This represents 1.0% of all adverse event reports for OCRELIZUMAB.
539
Reports of Mobility decreased with OCRELIZUMAB
1.0%
of all OCRELIZUMAB reports
9
Deaths
199
Hospitalizations
How Dangerous Is Mobility decreased From OCRELIZUMAB?
Of the 539 reports, 9 (1.7%) resulted in death, 199 (36.9%) required hospitalization, and 5 (0.9%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 539 reports have been filed with the FAERS database.
What Other Side Effects Does OCRELIZUMAB Cause?
Covid-19 (11,454)
Fatigue (5,704)
Urinary tract infection (3,618)
Headache (3,036)
Multiple sclerosis (2,609)
Asthenia (2,509)
Nasopharyngitis (2,479)
Gait disturbance (2,384)
Pneumonia (2,333)
Pain (2,327)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which OCRELIZUMAB Alternatives Have Lower Mobility decreased Risk?
OCRELIZUMAB vs OCRIPLASMIN
OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE
OCRELIZUMAB vs OCTREOTIDE
OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE